AbbVie's Q2 2025 Earnings Reaffirm Gilgamesh Acquisition's Potential

AbbVie reported Q2 2025 earnings, with Skyrizi and Rinvoq accounting for $6.4 billion in global sales, 41% of total revenues. These products are demonstrating their growth potential, strengthening the case for the Gilgamesh acquisition. The acquisition is expected to enhance AbbVie's immunology portfolio and drive long-term growth.

AbbVie Inc. (NYSE: ABBV) reported its Q2 2025 earnings on July 2, 2025, with notable performance from its key products, Skyrizi and Rinvoq, which accounted for $6.4 billion in global sales, representing 41% of total revenues. The company's earnings report highlights the potential growth of these products, bolstering the case for the proposed acquisition of Gilgamesh Pharmaceuticals.

The earnings report showed resilience in AbbVie's immunology and oncology segments, with adjusted diluted EPS rising by 12.1% year-over-year. The company's guidance increase signals confidence in offsetting the declining revenue of Humira. The positive Phase 3 trial results for a Genmab/AbbVie blood cancer therapy, which demonstrated a 79% reduction in disease progression, further underscore AbbVie's focus on combination therapies.

The Gilgamesh acquisition, valued at approximately $1 billion, aims to expand AbbVie's mental health therapeutics portfolio. Gilgamesh Pharmaceuticals, a privately held company founded in 2019, is developing novel treatments for mental illness using psychedelics. The company's proprietary discovery platform, powered by Artificial Intelligence (AI), enables it to identify and classify new psychoactive entities more accurately. Gilgamesh's pipeline includes product candidates against depression and opioid abuse.

One of Gilgamesh's most advanced product candidates, GM-2505, demonstrated its therapeutic capacity in moderate to severe major depressive disorder (MDD) in a Phase IIa trial. The product induced remission in 94% of trial participants within the first 29 days of treatment, showcasing its fast-acting efficacy. This product candidate is a psychedelic, non-hallucinogenic, serotonin 2A receptor agonist designed to be administered in-clinic under medical supervision.

The acquisition of Gilgamesh aligns with AbbVie's strategy to diversify into high-growth therapeutic areas. The company's neuroscience business development activities, including the acquisition of Cerevel Therapeutics and Aliada Therapeutics, further support this strategy. The integration of Gilgamesh's pipeline would enhance AbbVie's neuroscience portfolio, potentially driving long-term growth.

AbbVie's stock performance has been robust, with a strategy of purchasing high-volume stocks and holding for one day achieving a 166.71% return from 2022 to the present. This highlights the role of liquidity concentration in short-term performance, particularly in volatile markets.

In conclusion, AbbVie's Q2 2025 earnings report and the proposed Gilgamesh acquisition position the company for continued growth in its immunology and neuroscience portfolios. The acquisition of Gilgamesh's innovative mental health therapeutics pipeline is expected to drive long-term value for investors.

References:
[1] https://www.ainvest.com/news/abbvie-surges-0-3-earnings-acquisition-hopes-1-2b-volume-hits-top-500-rank-2508/
[2] https://seekingalpha.com/article/4812797-abbvie-h1-2025-earnings-strengthen-case-for-targeting-gilgamesh-acquisition